A detailed history of Everett Harris & CO transactions in Novo Nordisk A S stock. As of the latest transaction made, Everett Harris & CO holds 6,438,614 shares of NVO stock, worth $563 Million. This represents 9.58% of its overall portfolio holdings.

Number of Shares
6,438,614
Previous 6,484,754 0.71%
Holding current value
$563 Million
Previous $926 Million 17.18%
% of portfolio
9.58%
Previous 11.92%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

SELL
$119.07 - $145.42 $5.49 Million - $6.71 Million
-46,140 Reduced 0.71%
6,438,614 $767 Million
Q2 2024

Aug 01, 2024

SELL
$122.71 - $146.91 $1.55 Million - $1.85 Million
-12,618 Reduced 0.19%
6,484,754 $926 Million
Q1 2024

Apr 19, 2024

SELL
$102.11 - $135.92 $1.57 Million - $2.1 Million
-15,417 Reduced 0.24%
6,497,372 $834 Million
Q4 2023

Jan 18, 2024

SELL
$87.78 - $105.45 $2.32 Million - $2.79 Million
-26,413 Reduced 0.4%
6,512,789 $674 Million
Q3 2023

Oct 23, 2023

BUY
$90.94 - $199.54 $295 Million - $648 Million
3,246,806 Added 98.62%
6,539,202 $595 Million
Q2 2023

Jul 26, 2023

SELL
$155.98 - $172.65 $3.02 Million - $3.34 Million
-19,370 Reduced 0.58%
3,292,396 $533 Million
Q1 2023

Apr 24, 2023

SELL
$132.34 - $159.14 $998,240 - $1.2 Million
-7,543 Reduced 0.23%
3,311,766 $527 Million
Q4 2022

Jan 20, 2023

BUY
$102.55 - $135.33 $330,108 - $435,627
3,219 Added 0.1%
3,319,309 $0
Q3 2022

Oct 21, 2022

BUY
$95.28 - $116.93 $5.18 Million - $6.36 Million
54,370 Added 1.67%
3,316,090 $330 Million
Q2 2022

Jul 22, 2022

SELL
$103.24 - $121.81 $1.13 Million - $1.33 Million
-10,943 Reduced 0.33%
3,261,720 $363 Million
Q1 2022

Apr 22, 2022

BUY
$93.1 - $112.54 $576,754 - $697,185
6,195 Added 0.19%
3,272,663 $363 Million
Q4 2021

Feb 02, 2022

SELL
$95.88 - $117.08 $480,838 - $587,156
-5,015 Reduced 0.15%
3,266,468 $366 Million
Q3 2021

Nov 03, 2021

SELL
$84.42 - $106.62 $244,986 - $309,411
-2,902 Reduced 0.09%
3,271,483 $314 Million
Q2 2021

Jul 29, 2021

BUY
$67.66 - $84.76 $970,312 - $1.22 Million
14,341 Added 0.44%
3,274,385 $274 Million
Q1 2021

May 13, 2021

BUY
$67.06 - $75.82 $2.54 Million - $2.87 Million
37,873 Added 1.18%
3,260,044 $220 Million
Q4 2020

Feb 04, 2021

BUY
$63.89 - $73.8 $1.15 Million - $1.32 Million
17,946 Added 0.56%
3,222,171 $225 Million
Q3 2020

Nov 03, 2020

BUY
$63.69 - $70.22 $722,563 - $796,645
11,345 Added 0.36%
3,204,225 $222 Million
Q2 2020

Jul 29, 2020

BUY
$58.54 - $67.94 $2.18 Million - $2.53 Million
37,168 Added 1.18%
3,192,880 $209 Million
Q1 2020

Apr 29, 2020

BUY
$49.46 - $64.78 $1.77 Million - $2.31 Million
35,695 Added 1.14%
3,155,712 $190 Million
Q4 2019

Jan 27, 2020

SELL
$49.86 - $58.26 $45,173 - $52,783
-906 Reduced 0.03%
3,120,017 $181 Million
Q3 2019

Nov 06, 2019

BUY
$47.54 - $53.43 $188,971 - $212,384
3,975 Added 0.13%
3,120,923 $161 Million
Q2 2019

Aug 13, 2019

BUY
$46.79 - $52.47 $65,973 - $73,982
1,410 Added 0.05%
3,116,948 $159 Million
Q1 2019

May 13, 2019

BUY
$46.36 - $52.63 $302,962 - $343,937
6,535 Added 0.21%
3,115,538 $163 Million
Q4 2018

Feb 13, 2019

BUY
$41.54 - $47.25 $858,424 - $976,421
20,665 Added 0.67%
3,109,003 $143 Million
Q3 2018

Nov 14, 2018

SELL
$46.76 - $51.24 $734,132 - $804,468
-15,700 Reduced 0.51%
3,088,338 $146 Million
Q2 2018

Jul 27, 2018

BUY
$44.29 - $50.42 $172,952 - $196,890
3,905 Added 0.13%
3,104,038 $143 Million
Q1 2018

Apr 20, 2018

BUY
$48.49 - $58.14 $532,177 - $638,086
10,975 Added 0.36%
3,100,133 $153 Million
Q4 2017

Feb 01, 2018

SELL
$47.53 - $53.73 $537,089 - $607,149
-11,300 Reduced 0.36%
3,089,158 $166 Million
Q3 2017

Oct 11, 2017

BUY
$41.15 - $49.22 $128 Million - $153 Million
3,100,458
3,100,458 $149 Million

Others Institutions Holding NVO

About NOVO NORDISK A S


  • Ticker NVO
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,257,289,984
  • Market Cap $197B
  • Description
  • Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...
More about NVO
Track This Portfolio

Track Everett Harris & CO Portfolio

Follow Everett Harris & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Everett Harris & CO , based on Form 13F filings with the SEC.

News

Stay updated on Everett Harris & CO with notifications on news.